<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02285179</url>
  </required_header>
  <id_info>
    <org_study_id>M14POS</org_study_id>
    <nct_id>NCT02285179</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen</brief_title>
  <acronym>Poseidon</acronym>
  <official_title>Phase I/Prospective Randomized Phase II Trial Of the Safety and Efficacy of Tamoxifen in Combination With GDC-0032 Compared With Tamoxifen alONe.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>EurocanPlatform</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rather</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed as a phase 1 dose escalation study followed by a randomised phase II&#xD;
      study. The study will be performed in three different centres: Addenbrooke &amp; Cambridge&#xD;
      university (Cambridge, UK), Netherlands Cancer Institute Amsterdam), and Vall d'Hebron&#xD;
      Hospital (Barcelona, Spain).&#xD;
&#xD;
      Three to six patients will be followed for one completed cycle of therapy (28 days) and&#xD;
      subsequent enrolment of new cohorts will be based on the safety assessment in that first&#xD;
      cycle and the documentation of dose limiting toxicities. To determine the safety and efficacy&#xD;
      of tamoxifen in combination with the isoform selective Pi3K inhibitor GDC-0032 compared with&#xD;
      tamoxifen alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the recommended phase II dose (RPTD) of GDC-0032 in combination with tamoxifen&#xD;
      in hormone receptor positive, HER2 negative metastatic breast cancer patients who have&#xD;
      progressed after prior endocrine treatment .Description of toxicity profile, severity and&#xD;
      frequency of adverse events (observed with the combination of GDC-0032 and tamoxifen To&#xD;
      evaluate the safety and tolerability of GDC-0032 in combination with tamoxifen, recording&#xD;
      adverse events using CTCAE v. 4.0 criteria To describe the pharmacokinetics of GDC-0032 in&#xD;
      combination with tamoxifen To investigate the possibility of major drug-drug interactions&#xD;
      (PK) To obtain proof of target inhibition by selected pharmacodynamic measurements To look&#xD;
      for preliminary evidence of anti-tumour activity To assess the status of potential biomarkers&#xD;
      for drug response like PIK3CA gene mutations, relevant proteins and phospho-proteins in the&#xD;
      PI3K pathway, circulating tumour DNA (ct-DNA) To assess germline DNA sequence for&#xD;
      pharmacogenetics studies&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Inclusion stopped due to COVID-19&#xD;
  </why_stopped>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>double blinded study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with MTD toxicity</measure>
    <time_frame>4 weeks</time_frame>
    <description>MTD toxicity will be assessed in the first 28 days of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Number of patients with adverse events</measure>
    <time_frame>2 year</time_frame>
    <description>Number of patients with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Number of patients with germline DNA sequence</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients with germline DNA sequence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Number of patients with a response to protocol treatment</measure>
    <time_frame>2 year</time_frame>
    <description>Number of patients with a response to protocol treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>tamoxifen and GDC-0032</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg tamoxifen QD and 4 MG GDC-0032 QOD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tamoxifen and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 mg tamoxifen QD and placebo QOD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0032</intervention_name>
    <description>Dose of GDC-0032 given orally, once daily (total daily dose) level -1: 2 mg Q.O.D GDC-0032 level 1: (starting) 2 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd level 2: 4 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd</description>
    <arm_group_label>tamoxifen and GDC-0032</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>daily dose of 20 mg</description>
    <arm_group_label>tamoxifen and GDC-0032</arm_group_label>
    <arm_group_label>tamoxifen and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Minimum age for inclusion 18 years&#xD;
&#xD;
          -  The patient has a WHO performance status ≤ 2&#xD;
&#xD;
          -  Premenopausal and postmenopausal female breast cancer patient with histological proven&#xD;
             ER and/or PR positive*, HER2 negative breast cancer (based on the most recent&#xD;
             assessment of ER and PR status from primary breast cancer or from recurrent or&#xD;
             metastatic disease). If a patient is premenopausal by clinical and analytical&#xD;
             assessment (defined as having premenopausal follicle stimulating hormone (FSH) and/or&#xD;
             plasma estradiol levels), she should also receive a LHRH agonist.&#xD;
&#xD;
          -  The patient's breast cancer must be negative for HER2 over-expression by IHC (IHC&#xD;
             score ≤1+) or for HER2 gene amplification by FISH or CISH or SISH&#xD;
&#xD;
          -  Patients must have either measurable or evaluable disease by RECIST criteria version&#xD;
             1.1.&#xD;
&#xD;
          -  The patient has recurrent or metastatic breast cancer that is refractory to an&#xD;
             endocrine therapy defined as the occurrence of either of the following while the&#xD;
             patient is on endocrine therapy:&#xD;
&#xD;
          -  Disease progression of locally advanced or metastatic breast cancer&#xD;
&#xD;
          -  Disease recurrence of early stage breast cancer (i.e., recurrence while receiving&#xD;
             adjuvant treatment with endocrine therapy)&#xD;
&#xD;
          -  Availability of a representative tumour tissue specimen:&#xD;
&#xD;
          -  If a patient is currently receiving bisphosphonates, the patient must have received&#xD;
             the bisphosphonates for at least 1 month before starting study treatment.&#xD;
&#xD;
          -  The patient has adequate organ and marrow function, as defined in protocol.&#xD;
&#xD;
          -  The patient has no other diagnosis of malignancy or evidence of other malignancy for 2&#xD;
             years before screening for this study (except non-melanoma skin cancer or in situ&#xD;
             carcinoma of the cervix).&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks.&#xD;
&#xD;
          -  Fasting glucose ≤ 120 mg/dL (=6.66 mmol/L) and HbA1c ≤ ULN.&#xD;
&#xD;
        exclusion criteria:&#xD;
&#xD;
          -  The following restrictions on prior anticancer therapy apply;&#xD;
&#xD;
          -  Endocrine therapies or small molecule targeted (non-cytotoxic) inhibitors within 2&#xD;
             weeks or 5 half-lives of the compound or active metabolites, whichever is longer,&#xD;
             before the first dose of the study treatment are not allowed&#xD;
&#xD;
             --No more than 5 prior chemotherapeutic regimens for metastatic breast cancer&#xD;
&#xD;
          -  Radiation therapy within 2 weeks before the first dose of study treatment, unless of&#xD;
             palliative intent, not compromising bone marrow function&#xD;
&#xD;
          -  Cytotoxic chemotherapy within 3 weeks, or nitrosoureas or mitomycin C within 6 weeks&#xD;
             before the first dose of the study treatment&#xD;
&#xD;
          -  Antibody therapy within 4 weeks before the first dose of the study treatment&#xD;
&#xD;
          -  Major surgery or not recovered from major surgery, within 4 weeks before the first&#xD;
             dose of study treatment&#xD;
&#xD;
          -  Other malignancy with the exclusion of carcinoma in situ.&#xD;
&#xD;
          -  The patient has not recovered from toxicity due to prior therapy to grade ≤1 or to&#xD;
             pre-therapy baseline. Patients with grade 2 peripheral neuropathy or grade 2 alopecia&#xD;
             related to prior therapies are eligible&#xD;
&#xD;
          -  The patient has untreated, symptomatic, or progressive brain metastases. -The patient&#xD;
             has a history of thrombo-embolic disease or is currently receiving anticoagulation&#xD;
             with therapeutic doses of warfarin.&#xD;
&#xD;
          -  The patient has prothrombin time/ International Normalized Ratio (PT/ INR) or partial&#xD;
             thromboplastin time (PTT) test results at screening that are above 1.3 x the&#xD;
             laboratory upper limit of normal.&#xD;
&#xD;
          -  Patients with a history of Crohn's disease or ulcerative colitis or other forms of&#xD;
             autoimmune colitis&#xD;
&#xD;
          -  The patient has uncontrolled significant intercurrent illness&#xD;
&#xD;
          -  History of clinically significant cardiac or pulmonary dysfunction-The patient has a&#xD;
             type 1 or 2 diabetes requiring daily anti-hyperglycemic medication&#xD;
&#xD;
          -  Corticosteroid use equivalent to more than 10mg prednisone daily&#xD;
&#xD;
          -  The patient is known to be positive for the human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  The patient has a previously identified allergy or hypersensitivity to components of&#xD;
             the study treatment formulation(s).&#xD;
&#xD;
          -  The patients is unable or unwilling to abide by the study protocol or cooperate fully&#xD;
             with the investigator or designee&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine C. Linn, prof.dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NKI-AvL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Baird, dr</last_name>
    <role>Study Chair</role>
    <affiliation>Cambridge University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Gasthuis</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haaglanden Medisch Centrum</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Groep Twente</name>
      <address>
        <city>Hengelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUMC</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital/VHIO</name>
      <address>
        <city>Barcelona</city>
        <zip>080035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital ICO-Hospitalet (Bellvitge)</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Sant Joan de Reus</name>
      <address>
        <city>Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cambridge</name>
      <address>
        <city>Cambridge</city>
        <zip>CB20QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 21, 2014</study_first_submitted>
  <study_first_submitted_qc>November 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2014</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GDC-0032</keyword>
  <keyword>Pi3K inhibitor</keyword>
  <keyword>tamoxifen</keyword>
  <keyword>hormone receptor positive</keyword>
  <keyword>RECIST</keyword>
  <keyword>pharmacodynamic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

